乳腺癌组织学切片与细胞学标本中通过荧光原位杂交评估HER2基因状态的相关性
Correlation of HER2 gene status assessment by fluorescence in situ hybridization between histological sections and cytological specimens of breast cancer.
作者信息
Nishimura Rieko, Kagawa Akihiro, Tamogami Sachiko, Kojima Kenta, Satou Masakazu, Yamashita Natsumi, Teramoto Norihiro, Aogi Kenjiro
机构信息
Department of Clinical Laboratory, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, Ehime, 791-0280, Japan.
Division of Clinical Biostatistics, Section of Cancer Prevention and Epidemiology, Clinical Research Center, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
出版信息
Breast Cancer. 2016 Mar;23(2):211-5. doi: 10.1007/s12282-014-0552-0. Epub 2014 Jul 18.
BACKGROUND
While HER2 gene detection in cytological specimens using fluorescence in situ hybridization (FISH) has been reported, the appropriate criteria for such specimens remain controversial.
METHODS
Fine needle aspiration (FNA) samples collected from surgically resected breast cancer specimens were rinsed in a cytopreservative solution containing fixative. Then, slides of the FNA samples were prepared by liquid-based cytology (LBC) (ThinPrep system, Hologic) according to the manufacturer's instructions, and a PathVision HER2 DNA probe kit (Abbott) was used for FISH staining. The results were evaluated using an automated MetaCyte imaging system (MetaSystems, Altlussheim, Germany). HER2 gene amplification was scored using the HER2/chromosome enumeration probe 17 (CEP17) signal count ratio as follows: amplified, >2.2; equivocal, 1.8-2.2; and unamplified, <1.8. The cytology results were compared with the histology results from concordant cases.
RESULTS
Successful results were obtained in 98 of 100 cases, and results from the FNA specimens were in agreement with those from the histological sections in 97 of these 98 cases (accuracy rate, 99 %; kappa, 0.962).
CONCLUSIONS
FISH-based assessment of the HER2 gene status is consistent between histological sections and cytological specimens of breast cancer.
背景
虽然已有报道使用荧光原位杂交（FISH）技术在细胞学标本中检测HER2基因，但此类标本的合适标准仍存在争议。
方法
从手术切除的乳腺癌标本中采集的细针穿刺（FNA）样本在含有固定剂的细胞保存液中冲洗。然后，根据制造商的说明，使用液基细胞学（LBC）（ThinPrep系统，Hologic公司）制备FNA样本的玻片，并使用PathVision HER2 DNA探针试剂盒（雅培公司）进行FISH染色。使用自动MetaCyte成像系统（MetaSystems公司，德国阿尔特卢斯海姆）评估结果。使用HER2/染色体计数探针17（CEP17）信号计数比评估HER2基因扩增情况，如下：扩增，>2.2；可疑，1.8 - 2.2；未扩增，<1.8。将细胞学结果与相符病例的组织学结果进行比较。
结果
100例中有98例获得成功结果，这98例中的97例FNA标本结果与组织学切片结果一致（准确率99%；kappa值，0.962）。
结论
基于FISH的HER2基因状态评估在乳腺癌组织学切片和细胞学标本之间具有一致性。
Zotero 插件